Purdue Pharma, known for its role in the opioid crisis, has received FDA approval for a new auto-injector device to reverse opioid overdoses. The device, Zurnai, uses nalmefene, a stronger form of naloxone. Despite Purdue’s controversial history, the company plans to sell Zurnai at cost to help address the crisis it contributed to. The approval comes amidst a debate over the effectiveness of overdose-reversal medications and concerns about inducing severe withdrawal. The decision also follows the Supreme Court’s rejection of a settlement that would have granted Purdue immunity from civil lawsuits related to the opioid crisis.
Source link
FDA OK’s Purdue Pharma’s new overdose-reversal medication
